Annotation of CYP2C19*1, CYP2C19*2, CYP2C19*3
CYP2C19 *2/*2 + *3/*3 is associated with decreased clearance of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.
Healthy individuals (negative for Helicobacter pylori) with the *2/*2 or *3/*3 genotype had decreased apparent oral clearance (CL/F; units = mL*kg/min), increased area under the concentration-time curve from 0-24 hours (AUC0-24; units = ng*h/mL) and increased maximum plasma concentration (Cmax; units = ng/mL) of rabeprazole, as compared to those with the *1/*1, *1/*2 or *1/*3 genotype. No significant association was seen for terminal elimination half-life (t1/2; units = hours). Please note that these genotypes were referred to by their previous designations of m1 (*2) and m2 (*3).
From Publication
Gene
Phenotype Category
Association Significance
PharmGKB ID
Score More info on scoring
Evidence for Clinical Annotations
This annotation has been used as evidence for the following clinical annotations.
Study Parameters
1.
Study type
Study size
Association p-value
Allele frequency
Biogeographical group More info on groups
Population description
Study Cohort: p-value refers to difference in AUC0-24.
2.
Study type
Study size
Association p-value
Allele frequency
Biogeographical group More info on groups
Population description
Study Cohort: p-value refers to difference in CL/F.
3.
Study type
Study size
Association p-value
Allele frequency
Biogeographical group More info on groups
Population description
Study Cohort: p-value refers to difference in Cmax.
4.
Study type
Study size
Association p-value
Allele frequency
Biogeographical group More info on groups
Population description
Study Cohort: p-value refers to difference in t1/2.
Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.